Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
RIGL

RIGL - Rigel Pharmaceuticals Inc Stock Price, Fair Value and News

$35.22-2.03 (-5.45%)
Market Closed

75/100

RIGL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

75/100

RIGL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$48.34

Target 3M

$39.51

Target 6M

$42.28

RIGL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RIGL Price Action

Last 7 days

-6.4%

Last 30 days

-18.2%

Last 90 days

11.4%

Trailing 12 Months

58.9%

RIGL RSI Chart

RIGL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RIGL Valuation

Market Cap

639.3M

Price/Earnings (Trailing)

5.64

Price/Sales (Trailing)

2.27

EV/EBITDA

4.75

Price/Free Cashflow

9.38

RIGL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$48.34

Target 3M

$39.51

Target 6M

$42.28

RIGL Fundamentals

RIGL Revenue

Revenue (TTM)

282.1M

Rev. Growth (Yr)

25.59%

Rev. Growth (Qtr)

-31.69%

RIGL Earnings

Earnings (TTM)

113.3M

Earnings Growth (Yr)

124.62%

Earnings Growth (Qtr)

-53.2%

RIGL Profitability

EBT Margin

40.53%

Return on Equity

96.34%

Return on Assets

46.72%

Free Cashflow Yield

10.66%

RIGL Investor Care

Shares Dilution (1Y)

3.04%

Diluted EPS (TTM)

6.19

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025203.1M267.9M282.1M0
2024120.3M130.3M157.5M179.3M
2023129.6M126.6M132.4M116.9M
202285.0M88.5M89.4M120.2M
2021133.9M144.1M147.3M149.2M
2020102.4M108.0M105.6M108.6M
201957.1M65.8M81.7M59.3M
201802.7M7.6M44.5M
201718.9M10.3M7.5M4.5M
201631.7M35.2M25.9M20.4M
201516.2M21.4M28.6M28.9M
201400015.4M
201302.9M1.4M7.2M
20125.7M6.6M2.3M2.3M
2011084.9M44.8M4.8M
2010000125.0M
20090000
Get all data in R, Python etc through our Historical Stock Data APIs

About Rigel Pharmaceuticals Inc

RIGL
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. It also develops Fostamatinib that has conducted phase III clinical trials for the treatment of warm autoimmune hemolytic anemia; has completed FOCUS phase III clinical trial for the treatment of hospitalized high-risk patients COVID-19; and that is in phase II/III clinical trials for the treatment of COVID-19 in hospitalized patients. In addition, the company's other clinical programs include interleukin receptor-associated kinase inhibitor program and a receptor-interacting serine/threonine-protein kinase inhibitor program in clinical development with partner Eli Lilly and Company. Further, it has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company was incorporated in 1996 and is headquartered in South San Francisco, California.
 CEO
 WEBSITErigel.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES155

Rigel Pharmaceuticals Inc Frequently Asked Questions

RIGL is the stock ticker symbol of Rigel Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Rigel Pharmaceuticals Inc is 639.29 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check RIGL's fair value in chart for subscribers.

The fair value guage provides a quick view whether RIGL is over valued or under valued. Whether Rigel Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Rigel Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RIGL.

As of Wed Jan 28 2026, RIGL's PE ratio (Price to Earnings) is 5.64 and Price to Sales (PS) ratio is 2.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RIGL PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Rigel Pharmaceuticals Inc has provided 0.025 (multiply by 100 for percentage) rate of return.